RS55590B1 - Nove podgrupe pacijenata za trombolizu - Google Patents

Nove podgrupe pacijenata za trombolizu

Info

Publication number
RS55590B1
RS55590B1 RS20170031A RSP20170031A RS55590B1 RS 55590 B1 RS55590 B1 RS 55590B1 RS 20170031 A RS20170031 A RS 20170031A RS P20170031 A RSP20170031 A RS P20170031A RS 55590 B1 RS55590 B1 RS 55590B1
Authority
RS
Serbia
Prior art keywords
stroke
patient
desmoteplase
patients
use according
Prior art date
Application number
RS20170031A
Other languages
English (en)
Serbian (sr)
Inventor
Mariola Söhngen
Alice Ebel
Yasir Alaa Shafeek Al-Rawi
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS55590(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07020401A external-priority patent/EP2050462A1/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of RS55590B1 publication Critical patent/RS55590B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RS20170031A 2007-10-18 2008-10-20 Nove podgrupe pacijenata za trombolizu RS55590B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07020401A EP2050462A1 (en) 2007-10-18 2007-10-18 Improved treatment of stroke patients
EP07022867 2007-11-26
EP08017954 2008-10-15
PCT/EP2008/008871 WO2009049914A2 (en) 2007-10-18 2008-10-20 Novel patient subgroups for thrombolysis
EP08838897.0A EP2211898B1 (en) 2007-10-18 2008-10-20 Novel patient subgroups for thrombolysis

Publications (1)

Publication Number Publication Date
RS55590B1 true RS55590B1 (sr) 2017-06-30

Family

ID=40567844

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170031A RS55590B1 (sr) 2007-10-18 2008-10-20 Nove podgrupe pacijenata za trombolizu

Country Status (28)

Country Link
US (2) US20100272704A1 (https=)
EP (1) EP2211898B1 (https=)
JP (2) JP5509085B2 (https=)
KR (1) KR20100089077A (https=)
CN (1) CN101903039B (https=)
AR (1) AR068914A1 (https=)
AU (1) AU2008314048B2 (https=)
BR (1) BRPI0817785A2 (https=)
CA (1) CA2702378A1 (https=)
CL (1) CL2009000752A1 (https=)
CY (1) CY1118417T1 (https=)
DK (1) DK2211898T3 (https=)
EA (1) EA020776B1 (https=)
ES (1) ES2611155T3 (https=)
HR (1) HRP20170001T1 (https=)
HU (1) HUE032867T2 (https=)
IL (1) IL205175A0 (https=)
LT (1) LT2211898T (https=)
MX (1) MX2010004157A (https=)
MY (1) MY159200A (https=)
NZ (1) NZ584640A (https=)
PL (1) PL2211898T3 (https=)
PT (1) PT2211898T (https=)
RS (1) RS55590B1 (https=)
SI (1) SI2211898T1 (https=)
TW (1) TWI482628B (https=)
WO (1) WO2009049914A2 (https=)
ZA (1) ZA201002548B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5244806A (en) * 1985-08-26 1993-09-14 Eli Lilly And Company DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
US5094953A (en) * 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
DK176140B1 (da) * 1988-07-20 2006-09-25 Schering Ag Patentabteilung Flagermusspyt-plasminogenaktivatorer
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US6008019A (en) * 1989-02-13 1999-12-28 Schering Aktiengesellschaft Plasminogen activator from saliva of the vampire bat
US5891664A (en) * 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
DE59204945D1 (de) * 1991-04-16 1996-02-15 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
US5595736A (en) * 1991-04-22 1997-01-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders
ES2107790T3 (es) * 1992-12-04 1997-12-01 Schering Ag Inhibidor de trombina procedente de la saliva de protostomias.
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5731186A (en) * 1996-02-05 1998-03-24 Schering Aktiengesellschaft Method for the production of rDSPA α1
US6354999B1 (en) * 2000-01-14 2002-03-12 Florence Medical Ltd. System and method for detecting, localizing, and characterizing occlusions and aneurysms in a vessel
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20080213244A1 (en) * 2003-05-05 2008-09-04 Wolfgang Sohngen Glutamate Receptor Antagonists as Neuroprotectives
US20050085478A1 (en) * 2003-08-22 2005-04-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
CN101248083A (zh) * 2005-08-25 2008-08-20 比奥根艾迪克Ma公司 Nogo受体多肽和多肽片段及其用途

Also Published As

Publication number Publication date
US20100272704A1 (en) 2010-10-28
JP5509085B2 (ja) 2014-06-04
CL2009000752A1 (es) 2009-12-04
ES2611155T3 (es) 2017-05-05
ZA201002548B (en) 2011-06-29
EP2211898B1 (en) 2016-12-07
US20140314736A1 (en) 2014-10-23
HK1151233A1 (en) 2012-01-27
CN101903039B (zh) 2014-04-02
BRPI0817785A2 (pt) 2015-03-24
HUE032867T2 (en) 2017-11-28
KR20100089077A (ko) 2010-08-11
EA020776B1 (ru) 2015-01-30
CN101903039A (zh) 2010-12-01
DK2211898T3 (en) 2017-01-30
IL205175A0 (en) 2010-11-30
EA201070485A1 (ru) 2010-10-29
AU2008314048A1 (en) 2009-04-23
HRP20170001T1 (hr) 2017-02-24
NZ584640A (en) 2012-10-26
WO2009049914A3 (en) 2009-08-06
CY1118417T1 (el) 2017-06-28
LT2211898T (lt) 2017-01-25
JP2011500617A (ja) 2011-01-06
AU2008314048B2 (en) 2013-07-25
MY159200A (en) 2016-12-30
TW200927164A (en) 2009-07-01
AR068914A1 (es) 2009-12-16
EP2211898A2 (en) 2010-08-04
SI2211898T1 (sl) 2017-02-28
TWI482628B (zh) 2015-05-01
PT2211898T (pt) 2017-01-31
PL2211898T3 (pl) 2017-03-31
MX2010004157A (es) 2010-04-30
WO2009049914A2 (en) 2009-04-23
CA2702378A1 (en) 2009-04-23
JP2014065739A (ja) 2014-04-17

Similar Documents

Publication Publication Date Title
Bourekas et al. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke
Hattenbach et al. Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion
Lei et al. Effect of intravenous thrombolysis in acute ischemic stroke patients with cerebral microbleeds and analysis of risk factors for hemorrhagic transformation.
Wu et al. Assessing the clinical efficacy of recombinant tissue plasminogen activator on acute cerebral infarction
EP2050462A1 (en) Improved treatment of stroke patients
Chen et al. Low-dose tissue plasminogen activator is as effective as standard tissue plasminogen activator administration for the treatment of acute ischemic stroke
AU2008314048B2 (en) Novel patient subgroups for thrombolysis
Xianxian et al. The efficiency analysis of thrombolytic rt-PA combined with intravascular interventional therapy in patients with acute basilar artery occlusion
Zhu et al. Safety and efficacy of intravenous tirofiban infusion after mechanical thrombectomy in acute ischemic stroke: a retrospective observational study
Alexandre et al. Mechanical thrombectomy in patients with stroke due to large vessel occlusion in the anterior circulation and low baseline NIHSS score
Acampa et al. Safety of intravenous thrombolysis in ischemic stroke caused by left atrial myxoma
JP2011500617A5 (https=)
Ren et al. Thrombolytic effects of a combined therapy with targeted microbubbles and ultrasound in a 6 h cerebral thrombosis rabbit model
HK1151233B (en) Novel patient subgroups for thrombolysis
Connors Interventional stroke therapy: the potential benefit of direct intra-arterial infusion
Egashira et al. Efficacy and limitations of multimodal endovascular revascularization other than clot retrieval for acute stroke caused by large-vessel occlusion
Qureshi et al. Outcomes in acute ischemic stroke patients without angiographically documented arterial occlusion
Schellinger Stroke management in the early phase
Yin Acute basilar artery occlusion
Petrov et al. Iveta Tasheva, et al. Single Center Experience with Catheter Based Treatment in Acute Ischemic Stroke
Wong et al. Acute ischaemic stroke: management, recent advances and controversies
Oguro et al. Effect of one-shot intravenous 0.42 mega unit urokinase therapy in patients with acute ischemic stroke
Kim et al. Local intracranial intraarterial thrombolytic therapy in acute cerebral infarction
Csiba et al. Fibrin-degrading drugs in acute stroke
Csiba et al. Fibrin-degrading drugs